Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval

Stock Track

May 19

BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.

The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.

Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1172120087"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172120087\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172120087?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172120087","market":"sg","top_or_hot":-1,"title":"Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval","media":"Stock Track","content":"<p>BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.</p><p>The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.</p><p>Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-19 10:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.</p><p>The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.</p><p>Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06955","symbol_name":"博安生物","start_time":0,"source_url":"","article_id":"1172120087","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172120087","pubTimestamp":1779159162,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.The company announced a share repurchase plan, with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06955":"博安生物"},"translate_title":"个股赛道|博安生物盘中大涨14.97%因股份回购计划及澳门药物获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06955":1},"content_text":"BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}